Article of the day, September 8th, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Authors: Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder,  Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Juan Liu, Chen Huang, Sohail Mulla,  Yulei Wang, Ho Yeong Lim, Andrew X. Zhu and Ann-Lii Cheng.

Author Affiliations: UCLA Health Jonsson Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center, Beckman Institute at Illinois, Jiahui Health, University Medical Center Mainz, Paris Saclay Cancer Cluster (PSCC), SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE ALUMNI ASSOCIATION INC, Samsung Medical Center, N.N.Blokhin Russian Cancer Research Center, The University of Texas M.D. Anderson Cancer Center, National Taiwan University, et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.